2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Status
Unknown
2
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other solid neoplasm
3
Conditions
Carcinoma, Non-Small-Cell Lung
164
Breast Neoplasms
111
Colorectal Neoplasms
77
Neoplasms
64
Lung Neoplasms
61
Pancreatic Neoplasms
56
Stomach Neoplasms
52
Neoplasm Metastasis
51
Ovarian Neoplasms
45
Rectal Neoplasms
43
Esophageal Squamous Cell Carcinoma
38
Esophageal Neoplasms
38
Head and Neck Neoplasms
34
Squamous Cell Carcinoma of Head and Neck
32
Leukemia, Myeloid, Acute
32
Triple Negative Breast Neoplasms
25
Recurrence
25
Small Cell Lung Carcinoma
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Colonic Neoplasms
23
Nasopharyngeal Carcinoma
22
Glioblastoma
22
Uterine Cervical Neoplasms
21
Lymphoma
21
Lymphoma, Non-Hodgkin
20
Fallopian Tube Neoplasms
20
Prostatic Neoplasms
17
Melanoma
17
Sarcoma
16
Leukemia
16
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
9
Bevacizumab
8
toripalimab
7
senaparib
7
Fluorodeoxyglucose F18
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Fluorouracil
6
Gemcitabine
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
spartalizumab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Midazolam
3
Itraconazole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Solid Tumor
×
Drug Therapy
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled
NCT04214717
2023-03-28
DC-CIK
Yantai Yuhuangding Hospital
Phase NA
Unknown
60 enrolled
NCT04214730
2023-03-28
NK
Yantai Yuhuangding Hospital
Phase NA
Unknown
60 enrolled